Literature DB >> 8578836

Cross-reaction but no avidity change of the serum antibody response after influenza vaccination.

K A Brokstad1, R J Cox, D Major, J M Wood, L R Haaheim.   

Abstract

Pre- and post-vaccination sera from 19 volunteers were analysed by the haemagglutination inhibition (HI) test, virus neutralization (VN) assay and avidity enzyme-linked immunosorbent assay (ELISA). The sera were tested against the three strains in a commercial inactivated influenza vaccine; A/Beijing/353/89(H3N2); A/Taiwan/1/86 (H1N1) and B/Yamagata/16/88. Additionally, a range of earlier strains and one newer isolate were assayed for HI- and VN-antibodies. Large variations in the pre-vaccination HI titres were observed for the viruses tested. However, 8-9 days after vaccination HI titres increased to above the assumed protective level (HI > or = 40) in most subjects. Although a limited number of patients were analysed at each sampling point, the time-profile we observed in this study is consistent with data we have obtained in earlier trials (Cox, R.J. et al., Vaccine 1994, 12,993-999). The VN titres, on the other hand, were low against all influenza strains before and up to 6 days, but increased rapidly 8-9 days after vaccination. A recent H3N2 isolate, A/Beijing/32/92 (H3N2), which had drifted further away from the vaccine strain, reacted to low titres or were negative in both the HI and VN assays. No change in the serum avidity to the influenza surface antigens was detected after vaccination, whereas sera from subjects naturally infected with influenza showed an increase in avidity to the infecting virus strain. The increase in serum avidity observed in the infected subjects is probably due to the increased and prolonged antigenic stimulus provided by the replicating virus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8578836     DOI: 10.1016/0264-410x(95)00095-i

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques.

Authors:  W M Blay; S Gnanakaran; B Foley; N A Doria-Rose; B T Korber; N L Haigwood
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 2.  How innate immune mechanisms contribute to antibody-enhanced viral infections.

Authors:  Sukathida Ubol; Scott B Halstead
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

3.  Increased influenza-specific antibody avidity in HIV-infected women compared with HIV-infected men on antiretroviral therapy.

Authors:  Zhenwu Luo; Elizabeth Ogunrinde; Min Li; Lumin Zhang; Lisa Martin; Zejun Zhou; Zhiliang Hu; Tao Zhang; Zhen Li; Jiafeng Zhang; Bin Su; Tong Zhang; Hao Wu; Lei Ma; Guoyang Liao; Allison Ross Eckard; Maria Anna Julia Westerink; Sonya L Heath; Wei Jiang
Journal:  AIDS       Date:  2019-01-27       Impact factor: 4.177

4.  Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine.

Authors:  Wilbur H Chen; Alan S Cross; Robert Edelman; Marcelo B Sztein; William C Blackwelder; Marcela F Pasetti
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

5.  Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.

Authors:  Lisa C Lindesmith; Michael L Mallory; Taylor A Jones; Charles Richardson; Robert R Goodwin; Frank Baehner; Paul M Mendelman; Robert F Bargatze; Ralph S Baric
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

6.  Heterotypic humoral and cellular immune responses following Norwalk virus infection.

Authors:  Lisa C Lindesmith; Eric Donaldson; Juan Leon; Christine L Moe; Jeffrey A Frelinger; Robert E Johnston; David J Weber; Ralph S Baric
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

7.  Seroepidemiology of group C rotavirus infection in England and Wales.

Authors:  Miren Iturriza-Gómara; Ian Clarke; Ulrich Desselberger; David Brown; Daniel Thomas; Jim Gray
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

Review 8.  Immunological assessment of influenza vaccines and immune correlates of protection.

Authors:  Adrian Reber; Jacqueline Katz
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

9.  Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.

Authors:  Helmut Uphoff; Matthias An der Heiden; Brunhilde Schweiger; Hartmut Campe; Dietmar Beier; Carina Helmeke; Martina Littmann; Walter Haas; Silke Buda; Daniel Faensen; Marcel Feig; Doris Altmann; Ole Wichmann; Tim Eckmanns; Udo Buchholz
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240

10.  Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease.

Authors:  Maria Florencia Delgado; Silvina Coviello; A Clara Monsalvo; Guillermina A Melendi; Johanna Zea Hernandez; Juan P Batalle; Leandro Diaz; Alfonsina Trento; Herng-Yu Chang; Wayne Mitzner; Jeffrey Ravetch; José A Melero; Pablo M Irusta; Fernando P Polack
Journal:  Nat Med       Date:  2008-12-14       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.